-
Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML
Tettero, J. M., Buisman, Y., Ngai, L. L., Bachas, C., Gjertsen, B. T., Kelder, A., van de Loosdrecht, A. A., Manz, M. G., Pabst, T., Scholten, W., Ossenkoppele, G. J., Cloos, J. & de Leeuw, D. C., 21 Dec 2023, In: HemaSphere. 7, 12, p. E981Research output: Contribution to journal › Article › Academic › peer-review
-
Understanding differential technologies for detection of MRD and how to incorporate into clinical practice
Cloos, J., Ngai, L. L. & Heuser, M., 8 Dec 2023, In: Hematology. American Society of Hematology. Education Program. 2023, 1, p. 682-690Research output: Contribution to journal › Article › Academic › peer-review
-
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
Tettero, J. M., Ngai, L. L., Bachas, C., Breems, D. A., Fischer, T., Gjertsen, B. T., Gradowska, P., Griskevicius, L., Janssen, J. J. W. M., Juliusson, G., Maertens, J., Manz, M. G., Pabst, T., Passweg, J., Porkka, K., Valk, P. J. M., Löwenberg, B., Ossenkoppele, G. J. & Cloos, J., 1 Oct 2023, In: Haematologica. 108, 10, p. 2794-2798 5 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
